gadobenate dimeglumine (cont.)
IN THIS ARTICLE
What should I discuss with my healthcare provider before receiving gadobenate dimeglumine (Multihance)?Gadobenate dimeglumine can cause a life-threatening condition in people with advanced kidney disease. The symptoms of this condition include:
Before receiving this medication, tell your doctor if you have kidney disease or if you are on dialysis. You may not be able to receive gadobenate dimeglumine. To make sure you can safely receive this medication, tell your doctor if you have any of these other conditions:
FDA pregnancy category C. It is not known whether gadobenate dimeglumine will harm an unborn baby. Before you receive this medication, tell your doctor if you are pregnant. It is not known whether gadobenate dimeglumine passes into breast milk or if it could harm a nursing baby. Do not breast-feed for at least 24 hours after receiving gadobenate dimeglumine. If you use a breast pump during this time, throw out any milk you collect. Do not feed it to your baby. How should I take gadobenate dimeglumine (Multihance)?Gadobenate dimeglumine is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting during your MRI. Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when the medicine is injected. Your doctor or other healthcare provider may want to watch you for a short time after your test is over. This is to make sure you do not have any unwanted side effects or delayed reactions. Report Problems to the Food and Drug Administration You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088. Need help identifying pills and medications? |
Women's Health
Find out what women really need.
From WebMD
Featured Centers
Health Solutions From Our Sponsors
Featured Topics
Most Popular Topics
Medical Dictionary
Pill Identifier on RxList
- quick, easy,
pill identification
Find a Local Pharmacy
- including 24 hour, pharmacies

